India is on a fast track mode to develop a COVID-19 vaccine. Briefing media in New Delhi today, AIIMS Delhi Director Randeep Guleria informed that the two phases of Human trials will take around 3 months to complete.
AIIMS, Delhi has initiated the Human clinical trials today for the indigenously developed COVAXIN.
Dr. Guleria informed that initially the human trial will be conducted on 100 people. Terming development of an indigenous vaccine as a great achievement, he informed that the medical institute has received an overwhelming response in terms of volunteer registration for the trials.
Dr. Guleria said that before administration of the vaccine multiple tests of the health volunteers will be done.
He affirmed that only healthy individuals aged between 12 to 65 years will be inducted in the trials.
